Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $17,547.60 in Stock

Key Points

• Esperion Therapeutics' General Counsel, Benjamin Looker, sold 6,267 shares of the company's stock for $17,547.60, representing a 1.57% decrease in ownership.
• Shares of Esperion traded up 1.1% to $2.75, with a market cap of approximately $554.46 million and a negative PE ratio of -5.61.
• The company recently reported an earnings per share (EPS) of ($0.02), beating analysts' expectations, and generated $82.39 million in revenue for the quarter.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) General Counsel Benjamin Looker sold 6,267 shares of the stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $2.80, for a total value of $17,547.60. Following the completion of the sale, the general counsel directly owned 393,670 shares of the company's stock, valued at approximately $1,102,276. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Benjamin Looker also recently made the following trade(s):

• On Thursday, July 17th, Benjamin Looker sold 1,304 shares of Esperion Therapeutics stock. The stock was sold at an average price of $1.13, for a total value of $1,473.52.

Esperion Therapeutics Trading Up 1.1%

Shares of ESPR traded up $0.03 on Thursday, reaching $2.75. 6,300,044 shares of the company's stock traded hands, compared to its average volume of 4,974,958. The stock has a market cap of $554.46 million, a PE ratio of -5.61, a PEG ratio of 62.22 and a beta of 0.89. The stock's 50 day simple moving average is $1.92 and its two-hundred day simple moving average is $1.41. Esperion Therapeutics, Inc. has a 52-week low of $0.69 and a 52-week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The company had revenue of $82.39 million during the quarter, compared to the consensus estimate of $62.55 million. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%. Analysts forecast that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Wall Street Zen lowered Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, August 25th. HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Sivia Capital Partners LLC bought a new position in Esperion Therapeutics during the 2nd quarter valued at approximately $25,000. North Star Investment Management Corp. bought a new position in Esperion Therapeutics during the 2nd quarter valued at approximately $25,000. Meridian Wealth Management LLC bought a new position in Esperion Therapeutics during the 1st quarter valued at approximately $29,000. Synergy Asset Management LLC raised its position in Esperion Therapeutics by 3,496.3% during the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 30,138 shares during the last quarter. Finally, Boomfish Wealth Group LLC raised its position in Esperion Therapeutics by 29.5% during the 2nd quarter. Boomfish Wealth Group LLC now owns 45,306 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 10,309 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.